Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nasopharyngeal Carcinoma
Clinical trial register · China

Nasopharyngeal Carcinoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Guangzhou 66 Nanning 13 Zhongshan 12 Fuzhou 10 Wuzhou 7
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University56 Fudan University5 Zhejiang Cancer Hospital4 Zhongshan People's Hospital, Guangdong, China3 XIANG YANQUN3
Site location
Guangzhou66 Nanning13 Zhongshan12 Fuzhou10 Wuzhou7
All 45 locations
Target enrolment
to

Nasopharyngeal Carcinoma trials in China

102 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Sun Yat-sen University
Phase 2
138
Guangzhou
2026-10
Recruiting
Fujian Cancer Hospital
Phase 2
25
Fuzhou
2026-06-16
Recruiting
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
NCT07584499Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial Carcinoma, Rhabdomyosarcoma
DrugBecotatug Vedotin
Sun Yat-sen University
Phase 1
51
Guangzhou
2026-05-30
Not yet open
Sun Yat-sen University
Phase 3
442
Guangzhou
2026-05-08
Recruiting
Chongqing University Cancer Hospital
Phase 2
30
Chongqing
2026-02-09
Not yet open
Jiangsu Cancer Institute & Hospital
Observational
60
Nanjing
2025-12-25
Recruiting
Ming-Yuan Chen
Phase 3
346
Hefei, Fuzhou, Guangzhou, Shantou, Zhongshan, Zhuhai, Nanning, Wuzhou
2025-11-20
Recruiting
Sun Yat-sen University
Phase 2
70
Guangzhou
2025-05-16
Recruiting
Man Hu
Phase 3
386
Jinan
2025-05-07
Not yet open
A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma
NCT06781112TPF, Immunotherapy, Nasopharyngeal Carcinoma, Phase II Clinical Study
Weiwei Zhang
Phase 2
35
Chengdu
2025-01-20
Recruiting
Sun Yat-sen University
Phase 2
47
Guangzhou
2025-01-03
Recruiting
Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC
NCT06752239Nasopharyngeal Carcinoma, Quality of Life, Thyroid Diseases, Radiotherapy Side Effect
Jiangxi Provincial Cancer Hospital
Phase 3
474
Nanchang
2025-01-01
Active, closed
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
400
Guangzhou
2024-12-31
Recruiting
Affiliated Hospital of Nantong University
Not applicable
30
Nantong
2024-08-01
Recruiting
Sun Yat-sen University
Phase 3
586
Zhuhai
2024-07-30
Recruiting
Adebrelimab and Chemoradiotherapy in High-risk LANPC
NCT06349889Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
DrugAdebrelimab
Sun Yat-sen University
Phase 2
50
Xiamen, Guangzhou, Chengdu
2024-07-23
Recruiting
Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC
NCT06197776Multi-omics Technique, Nasopharyngeal Carcinoma, Recurrent and Metastatic Nasopharyngeal Carcinoma, Efficacy of Chemoradiotherapy and Immunotherapy
Sun Yat-sen University
Observational
50
Guangzhou
2024-07-15
Recruiting
Sun Yat-sen University
Phase 2
148
Guangzhou
2024-07-15
Recruiting
Deep Learning-based sbORN Diagnostic Model
NCT06463392Nasopharyngeal Carcinoma, Herpesvirus 4, Human
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
312
Guangzhou
2024-07-01
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
570
Guangzhou
2024-06-25
Recruiting
Sun Yat-sen University
Phase 2
216
Foshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen, Zhangjiang
2024-06-18
Recruiting
XIANG YANQUN
Phase 3
164
Guangzhou
2024-05-30
Recruiting
Sun Yat-sen University
Observational
908
Fuzhou, Guangzhou, Zhongshan, Nanning, Wuzhou
2024-05-29
Recruiting
Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma
NCT06516133Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
494
Guangzhou
2024-05-17
Recruiting
XIANG YANQUN
Phase 3
90
Guangzhou
2024-05-15
Not yet open
Sun Yat-sen University
Early Phase 1
12
Guangzhou
2024-05-01
Recruiting
Individualized Elective Neck Irradiation in NPC Patients
NCT06241612Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
470
Guangzhou
2024-04-16
Recruiting
Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.
NCT06533267Nasopharyngeal Carcinoma, Intensity Modulated Radiotherapy, Surgery
Sun Yat-sen University
Not applicable
442
Zhuhai
2024-03-25
Recruiting
Sun Yat-sen University
Phase 2
162
Guangzhou, Dongguan, Foshan, Shenzhen, Wuhan
2024-03-19
Recruiting
Jiangxi Provincial Cancer Hospital
Phase 3
264
Ganzhou, Guangzhou, Nanchang
2024-03-07
Recruiting
Sun Yat-sen University
Not applicable
112
Guangzhou
2024-03-04
Recruiting
Sun Yat-sen University
Phase 3
593
Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou, Shantou, Zhanjiang, Nanning
2024-03-01
Recruiting
Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
NCT06307314Nasopharyngeal Carcinoma, Head and Neck Cancer, Radiotherapy-induced Oral Mucositis, Biomarker
Nanfang Hospital, Southern Medical University
Observational
300
Guangzhou, Fuzhou, Huizhou, Jieyang, Meizhou
2024-02-01
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
121
Chongqing, Fuzhou, Guangzhou, Liuzhou, Luoyang, Zhengzhou, Wuhan, Changsha
2024-01-29
Recruiting
Hunan Cancer Hospital
Observational
50
Changsha
2024-01-11
Recruiting
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
NCT05941741Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy
DrugCadonilimab
Sun Yat-sen University
Phase 3
380
Guangzhou, Nanning, Nanchang
2024-01-10
Recruiting
The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC
NCT06182657Nasopharyngeal Carcinoma, Pathologic Complete Response, Tumor Microenvironment
Jiangxi Provincial Cancer Hospital
Observational
300
Nanchang
2024-01-01
Active, closed
Sun Yat-sen University
Observational
300
Guangzhou
2024-01-01
Not yet open
Fujian Cancer Hospital
Phase 3
476
Fuzhou
2024-01-01
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
386
Guangzhou
2023-12-04
Recruiting
Fudan University
Phase 3
266
Shanghai
2023-12-01
Recruiting
Ming-Yuan Chen
Not applicable
86
Guangzhou, Zhuhai
2023-11-01
Active, closed
Zhejiang Cancer Hospital
Phase 2
40
Hangzhou
2023-10-24
Recruiting
Sun Yat-sen University
Phase 3
504
Guangzhou
2023-10-09
Active, closed
Sun Yat-sen University
Phase 3
464
Guangzhou, Zhongshan, Nanning, Guiyang, Wuhan, Changsha
2023-09-07
Recruiting
Air Force Military Medical University, China
Phase 3
228
Xi'an
2023-09-01
Active, closed
Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
NCT05780372Nasopharyngeal Carcinoma, Radiotherapy; Complications
Sun Yat-sen University
Phase 3
474
Chongqing, Dongguan, Guangzhou, Liuzhou, Nanning, Nanchang, Hangzhou
2023-08-08
Recruiting
Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma
NCT05994170Nasopharyngeal Carcinoma, Intensity-Modulated Radiotherapy
Zhongshan People's Hospital, Guangdong, China
Not applicable
454
Zhongshan
2023-08-04
Active, closed
Sun Yat-sen University
Phase 3
490
Bengbu, Hefei, Beijing, Fuzhou, Dongguan, Guangzhou, Zhongshan, Nanning
2023-08-01
Recruiting
Sun Yat-sen University
Phase 3
424
Guangzhou
2023-05-20
Recruiting
Sun Yat-sen University
Phase 3
244
Guangzhou
2023-05-01
Active, closed
XIANG YANQUN
Phase 3
166
Guangzhou
2023-04-28
Active, closed
Zhejiang Cancer Hospital
Phase 2
89
Hangzhou
2023-04-21
Not yet open
Sun Yat-sen University
Phase 3
132
Guangzhou
2023-04-01
Recruiting
Zhongshan People's Hospital, Guangdong, China
Observational
12,000
Zhongshan
2023-02-01
Recruiting
Fudan University
Early Phase 1
24
Shanghai
2022-12-28
Not yet open
Sun Yat-sen University
Not applicable
236
Guangzhou
2022-11-30
Active, closed
Sun Yat-sen University
Phase 2
41
Guangzhou
2022-11-25
Active, closed
Compression Therapy as a Prophylactic Method Against CIPN: a Prospective Self-controlled Trial
NCT05531916Nasopharyngeal Carcinoma, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Sun Yat-sen University
Not applicable
182
Guangzhou
2022-11-21
Recruiting
Wei Jiang
Phase 3
440
Guilin, Wuzhou
2022-11-11
Recruiting
Ming-Yuan Chen
Not applicable
384
Zhuhai
2022-11-01
Active, closed
Yi Junlin
Phase 3
414
Beijing
2022-09-01
Active, closed
Sun Yat-sen University
Phase 2
105
Guangzhou
2022-08-17
Recruiting
Zhejiang Cancer Hospital
Phase 2
41
Hangzhou, Jiaxing, Jinhua, Lishui, Ningbo, Quzhou
2022-08-01
Recruiting
Cancer Hospital of Guangxi Medical University
Observational
43
Nanning
2022-07-30
Active, closed
PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma
NCT05340270Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor
Guangxi Medical University
Phase 2
150
Nanning
2022-07-15
Recruiting
Sun Yat-sen University
Observational
11,625
Guangzhou
2022-07-10
Active, closed
Sun Yat-sen University
Phase 3
450
Zhanjiang, Wuzhou, Guiyang, Changsha
2022-06-10
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
295
Beijing
2022-06-07
Recruiting
Sun Yat-sen University
Not applicable
264
Guangzhou
2022-06-01
Not yet open
Umbrella Biomarker-Guided Therapy in NPC
NCT04605562Nasopharyngeal Carcinoma
DrugsGalunisertib·Palbociclib
Sun Yat-sen University
Phase 2
206
Guangzhou
2022-06
Active, closed
Sun Yat-sen University
Phase 2
150
Guangzhou
2022-05-17
Active, closed
Sun Yat-sen University
Phase 3
452
Guangzhou
2022-05-11
Recruiting
Sichuan Cancer Hospital and Research Institute
Phase 2
170
Chengdu
2022-04-20
Recruiting
Sun Yat-sen University
Phase 3
556
Guangzhou
2022-04-17
Recruiting
Sun Yat-sen University
Phase 3
212
Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning
2022-04-01
Recruiting
Xinqiao Hospital of Chongqing
Phase 2
40
Chongqing
2022-03-01
Recruiting
Fudan University
Phase 3
459
Shanghai
2022-01-01
Recruiting
Taizhou Hospital
Phase 2
93
Taizhou
2022-01-01
Recruiting
Fudan University
Phase 3
366
Shanghai
2022-01-01
Recruiting
Immune Score Based Radiomics in Nasopharyngeal Carcinoma
NCT05126160Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Observational
494
Wuhan, Ningbo, Wenzhou, Hangzhou
2021-11-05
Recruiting
Sun Yat-sen University
Phase 3
266
Guangzhou
2021-08-16
Active, closed
Akeso
Phase 3
296
Hefei, Fuzhou, Xiamen, Dongguan, Guangzhou, Jiangmen, Shantou, Shenzhen
2021-08-16
Active, closed
Sun Yat-sen University
Phase 3
532
Beijing, Chongqing, Foshan, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2021-08-01
Not yet open
Sun Yat-sen University
Phase 2/3
622
Guangzhou
2021-07-01
Recruiting
Sun Yat-sen University
Phase 3
188
Guangzhou
2021-06-01
Recruiting
Sun Yat-sen University
Phase 3
218
Guangzhou, Zhongshan, Nanchang
2021-03-03
Active, closed
Fudan University
Phase 2
100
Shanghai
2020-11-01
Recruiting
Sun Yat-sen University
Phase 3
508
Guangzhou, Shaoguan, Zhongshan, Wuzhou
2020-08-18
Active, closed
Sun Yat-sen University
Phase 3
381
Guangzhou
2020-08-17
Recruiting
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 3
352
Guangzhou
2020-08-01
Recruiting
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
NCT04453813Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy, PD-1 Treatment
DrugToripalimab
Sun Yat-sen University
Phase 3
226
Guangzhou, Shaoguan, Zhongshan, Zhuhai, Wuzhou
2020-07-03
Recruiting
Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC
NCT04544969Circulating Tumor Cell, Nasopharyngeal Carcinoma, Distant Metastases.Clinical, Effects of Chemotherapy
Sun Yat-sen University
Observational
50
Guangzhou
2020-04-01
Recruiting
Zhongshan People's Hospital, Guangdong, China
Observational
40,000
Zhongshan, Wuzhou
2020-04-01
Active, closed
Sun Yat-sen University
Phase 2
246
Guangzhou
2020-01-31
Recruiting
Sun Yat-sen University
Phase 3
346
Guangzhou
2020-01-01
Active, closed
Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy
NCT04384627Nasopharyngeal Carcinoma, Induction Chemotherapy, Radiotherapy
Sun Yat-sen University
Phase 3
445
Foshan, Zhongshan
2019-12-01
Active, closed
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
NCT03840421Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
DrugsGemcitabine and cisplatin·Cisplatin
Sun Yat-sen University
Phase 3
468
Guangzhou
2019-04-03
Active, closed
TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma
NCT03306121Nasopharyngeal Carcinoma
DrugCCRT
Sun Yat-sen University
Phase 3
322
Guangzhou
2017-11-13
Recruiting
Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients
NCT03353467Nasopharyngeal Carcinoma, Endoscopic Surgery, Primary Napharyngeal Carcinama, Stage I Nasopharyngeal Cancer
Sun Yat-sen University
Not applicable
228
Guangzhou, Zhongshan, Nanning
2017-10-01
Active, closed
Sun Yat-sen University
Phase 2
164
Guangzhou
2017-02-04
Active, closed
Sun Yat-sen University
Phase 3
236
Guangzhou
2015-06
Rows per page Showing 1–102 of 102
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 November 2026. https://priyalifescience.com/clinical-trials-china/condition/nasopharyngeal-carcinoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 102 of those studies listing the condition Nasopharyngeal Carcinoma.

How many Nasopharyngeal Carcinoma trials are recruiting in China?

64 of the 102 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 10 have not yet opened recruitment, 28 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nasopharyngeal Carcinoma), 102 studies
PhaseStudiesRecruitingShare
Phase 3482847.1%
Phase 2261425.5%
Observational141213.7%
Not applicable1089.8%
Early Phase 1212%
Phase 1111%
Phase 2/3101%

Most active sponsors

Lead sponsors with the most studies (Nasopharyngeal Carcinoma)
Lead sponsorStudiesRecruiting
Sun Yat-sen University5631
Fudan University54
Zhejiang Cancer Hospital42
Jiangxi Provincial Cancer Hospital33
Ming-Yuan Chen33
Sichuan Baili Pharmaceutical Co., Ltd.32
XIANG YANQUN32
Zhongshan People's Hospital, Guangdong, China33
Fujian Cancer Hospital21
Affiliated Cancer Hospital & Institute of Guangzhou Medical University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.